Ras Mutation clinical trials

Explore recruiting ras mutation clinical trials.

Recruiting ras mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ras Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors

Germany, Netherlands, Spain, Denmark, France, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer

Spain, Belgium, France

Therapeutic exploratory (Phase II) EU CTIS Study details

FFCD 1605- OPTIPRIME: A phase II study evaluating FOLFOX + panitumumab according to a ‘stop-and-go’ strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line in patients with metastatic colorectal adenocarcinoma without a RAS mutation

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A dose-esalation phase I/II study in patients with RAS-mutated metastatic colorectal cancer to investigate safety and clinical actvitiy of the triple combination of: MEK-inhibitor binimetinib, pan-EGFR inhibitor lapatinib and the microtubule targeting agent (MTA) vinorelbine (RASTRIC)

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Ras Mutation trials by city

Ras Mutation in Toronto Ras Mutation in Vancouver Ras Mutation in Montreal Ras Mutation in Calgary Ras Mutation in Edmonton Ras Mutation in Ottawa Ras Mutation in Winnipeg Ras Mutation in Quebec City Ras Mutation in Hamilton Ras Mutation in Kitchener Ras Mutation in London Ras Mutation in Halifax Ras Mutation in New York Ras Mutation in Los Angeles Ras Mutation in Chicago Ras Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease